Login
  • Bookmark
  • PDF
  • Share
  • CaseIQ

N.R Jet Enterprises Ltd. v. National Pharmaceutical Pricing Authority, Delhi And Another

Bombay High Court
Apr 15, 2008
Important Paras
Please sign up to view Important Paras.
Smart Summary (Beta)

Judgment Summary — D.K. Deshmukh, J.

Factual and Procedural Background

These two writ petitions challenge the same order dated 12-6-2003 issued pursuant to a show cause notice dated 30-10-2002. The impugned order held Johnson & Johnson Ltd. and N.R. Jet Enterprises Ltd. jointly and severally liable to deposit an overcharged amount and interest under paragraph 13 of the Drugs (Price Control) Order, 1995 (DPCO'95) and section 7A of the Essential Commodities Act, 1955.

The drug at issue is "Raricap 40's tablets." The Central Government fixed the maximum retail selling price for Raricap 40 tablets at Rs. 16.24 by an order dated 7-8-1996. At that time Ethnor Limited (amalgamated with Johnson & Johnson Ltd. in 1994) / Johnson & Johnson Ltd. manufactured the drug. Johnson & Johnson allegedly continued to sell at a higher price (Rs. 24.57) and ceased manufacturing on 31-3-1997. From 1-4-1997 N.R. Jet began manufacturing and selling the drug. Johnson & Johnson had transferred the production rights and trademark to N.R. Jet in July 1996.

The show cause notice alleged collusion and that N.R. Jet was essentially a unit of Johnson & Johnson. The authority's order of 12-6-2003 held both companies liable for the overcharged amount and interest. Subsequent written submissions admitted the correct overcharged amount is Rs. 22,35,72,889/- (correcting an earlier figure of Rs. 25,00,78,500/-), and that this amount has been deposited by Johnson & Johnson Ltd., which does not seek its return.

Legal Issues Presented

  1. Whether, by the impugned order, the petitioners (Johnson & Johnson Ltd. and N.R. Jet) could be jointly held liable to pay interest of Rs. 12,97,41,819/- under section 7A of the Essential Commodities Act, 1955, on the overcharged amount.
  2. Whether the DPCO'95 price fixation order made on 7-8-1996 was binding on N.R. Jet (i.e., whether N.R. Jet is effectively a unit/assignee of Johnson & Johnson such that it is bound by the earlier order).
  3. Whether the High Court should exercise its extraordinary jurisdiction under Article 226 of the Constitution of India to interfere with the impugned order given the conduct alleged against the petitioners.

Arguments of the Parties

Petitioners' Arguments (Johnson & Johnson Ltd. and N.R. Jet)

  • Reliance on paragraph 8 of DPCO'95: a specific order fixing maximum price must be made in relation to an entity for that order to bind that entity. No specific order was made against N.R. Jet; therefore N.R. Jet cannot be said to have sold above the maximum price.
  • Johnson & Johnson contended the price fixation order was invalid; its validity is being challenged in the Delhi High Court.
  • Denial that N.R. Jet is a unit or subsidiary of Johnson & Johnson; N.R. Jet asserted independent corporate existence and that the DPCO order was not made against it.
  • Both petitioners denied liability to pay interest: under section 7A entitlement to recover interest arises only when there is a default by a person legally liable to make payment; an illegal demand (if the overcharged demand is illegal) cannot found liability or default. Under paragraph 13 of DPCO'95 the amount accrues only when liability has been finally determined; interest, if any, therefore could run only from the date of final determination (i.e., the impugned order).

Respondent's Arguments (Authority / Respondent No.1)

  • The conduct of the petitioners demonstrates collusion: Johnson & Johnson manufactured and sold at the higher price, then transferred trademark and manufacturing rights to N.R. Jet (a fully owned/controlled subsidiary) to continue selling at higher price, thereby defeating DPCO'95.
  • Because N.R. Jet is essentially a unit of Johnson & Johnson (based on shareholding, common address, and the nature of the holding companies), the price fixation order was binding on N.R. Jet and both are liable to pay the overcharged amount and interest from the date of overcharging.
  • The public interest purpose of the price-fixing order (ensuring availability of essential drugs at fair price) was defeated by the scheme; therefore the High Court should not exercise its extraordinary jurisdiction in favour of the petitioners.

Table of Precedents Cited

Precedent Rule or Principle Cited For Application by the Court
Mohammad Swalleh v. IIIrd Addl. District Judge, Meerut, (1988) 1 SCC 40 : AIR 1988 SC 94 High Court justified in declining to exercise jurisdiction under Article 226 even after finding the impugned order illegal, where the High Court is of the view that justice has been done by that order. The court relied on this Supreme Court authority to support its conclusion that, given the petitioners' conduct and the public interest purpose of the price control order, it was appropriate to decline to exercise extraordinary jurisdiction and to uphold the impugned order (subject to correction of the overcharged amount).

Court's Reasoning and Analysis

  1. Correction of the overcharged amount: The court accepted written submissions that the correct overcharged amount is Rs. 22,35,72,889/- rather than Rs. 25,00,78,500/-, and modified the impugned order accordingly. That amount has been deposited by Johnson & Johnson Ltd., which does not seek its return.
  2. Scope of the remaining dispute: With the overcharged amount deposited and not sought back, the sole remaining contested question was whether the authority was justified in holding both petitioners jointly liable to pay interest from dates prior to the impugned order — which requires determining if the DPCO'95 order bound N.R. Jet.
  3. Findings on factual matrix and control:
    • The price fixation order was made on 7-8-1996 against Johnson & Johnson Ltd., which at that time manufactured and sold Raricap tablets.
    • Johnson & Johnson continued to sell at a higher price until 31-3-1997; from 1-4-1997 N.R. Jet sold the drug at a higher price.
    • Admitted facts established that N.R. Jet had a paid-up capital of Rs.50,000 divided into 5000 shares; these shares were held equally by four wholly owned subsidiary companies of Johnson & Johnson Ltd., all sharing the same address and having no employees to conduct day-to-day affairs; those four companies are investment companies fully owned and controlled by Johnson & Johnson. These facts were admitted and undisputed.
    • Johnson & Johnson transferred its trademark and manufacturing rights to N.R. Jet in July 1996; N.R. Jet thus functioned as an assignee of Johnson & Johnson with rights limited to those assignable by Johnson & Johnson.
  4. Legal application to these facts:
    • The court reasoned that because N.R. Jet was fully owned and controlled through subsidiaries by Johnson & Johnson and operated effectively as an outfit of Johnson & Johnson, it was properly treated as the latter's unit for purposes of the price control order.
    • As assignee of the manufacture and trademark, N.R. Jet received only such rights as Johnson & Johnson had; since the DPCO order limited Johnson & Johnson's right to sell only at the fixed price, the assignee (N.R. Jet) would be subject to the same restriction.
    • Therefore the DPCO'95 price fixation that was binding on Johnson & Johnson was also binding on N.R. Jet; both sold above the fixed price and thus both were liable for the overcharge and for interest on amounts overcharged from the dates on which the overcharging occurred.
  5. On the exercise of extraordinary jurisdiction:
    • The court considered the petitioners' conduct — the transfer of trademark/manufacturing rights and continuation of higher pricing — to be a scheme designed to defeat a statutory order made in the public interest. The dominant purpose of DPCO orders is to ensure availability of essential drugs at fair prices.
    • Relying on the admitted facts and the public interest character of the order, the court concluded the petitioners' conduct disentitled them from relief in the exercise of the Court's discretionary jurisdiction under Article 226.
    • The court invoked the Supreme Court's decision in Mohammad Swalleh to support the proposition that a High Court may decline to exercise Article 226 jurisdiction even where an impugned order may be illegal, if the High Court finds that justice has been done by that order.
  6. Conclusion of analysis: For these reasons, the court found no ground to alter the impugned order's directions regarding interest; it confirmed the authority's calculation of interest and the holding of joint and several liability, subject only to correction of the overcharged principal amount to Rs. 22,35,72,889/-.

Holding and Implications

Holding: Both petitions are disposed of. The impugned order dated 12-6-2003 is not interfered with except that the overcharged principal is declared to be Rs. 22,35,72,889/- (in place of Rs. 25,00,78,500/-). The rest of the order is confirmed; the rule is disposed of and there is no order as to costs.

Implications:

  • Direct effect: Johnson & Johnson Ltd. and N.R. Jet are held jointly and severally liable under the impugned order for the corrected overcharged amount (Rs. 22,35,72,889/-) and for interest calculated on overcharged sums from the dates when the overcharging occurred (i.e., not restricted to running only from the date of the impugned order), as determined by the authority.
  • The court declined to exercise its extraordinary jurisdiction under Article 226 to grant relief to the petitioners, given the factual findings on control, transfer of rights, collusion and the public interest purpose of the price control order.
  • No broader legal precedent was articulated beyond the application of the Supreme Court authority cited (Mohammad Swalleh) to the discretionary question of invoking Article 226; the decision confirms the authority's order on the facts of this case.

This summary is based exclusively on the content of the opinion provided and does not add or infer facts beyond that text.

Show all summary ...

D.K Deshmukh, J.:— In both these petitions, the same order is challenged and therefore, both the petitions can be conveniently disposed of by common order.

2. By the order dated 12-6-2003 which is impugned in these petitions, Johnson & Johnson Ltd. which is petitioner in Writ Petition No. 4556 of 2003 and N.R Jet Enterprises Ltd. which is petitioner in Writ Petition No. 4264 of 2003 have been jointly and severally held liable to deposit an amount of Rs. 25,00,78,500/- (Rupees Twenty five crores seventy eight thousand five hundred only) under para 13 of DPCO'95 and interest amount of Rs. 12,97,41,819/- (Rupees Twenlve crores ninety seven lakhs forty one thousand eight hundred nineteen only) under section 7A of the Essential Commodities Act, 1955. As a result of written submissions filed on behalf of the respondents, now it is an admitted position that instead of Rs. 25,00,78,500/- the correct amount to be recovered is Rs. 22,35,72,889/- (Rupees Twenty two crores thirty five lakhs seventy two thousand eight hundred eighty nine only). It is also a common ground that this amount has actually been deposited by Johnson & Johnson Ltd. It was also stated before us that Johnson & Johnson Ltd. is not interested in claiming back that amount. Therefore, in these petitions the only question that is to be considered is “whether by the order impugned, the petitioners in these petitions could have been jointly held liable for payment of amount of Rs. 12,97,41,819/- as interest under section 7A of the Essential Commodities Act, 1955. Johnson & Johnson Ltd. is a pharmaceutical company incorporated under the provisions of the Companies Act, similarly N.R Jet Enterprises Ltd. (hereinafter referred to as N.R Jet) is also a pharmaceutical company incorporated under the provisions of the Companies Act. The present proceedings relate to the formulation known as “Raricap 40's tablets”. In exercise of the powers conferred by section 3 of the Essential Commodities Act, 1955, the Central Government from time to time made various Drugs (Price Control) Orders. The order with which we are concerned in these petitions is the Drugs (Price Control) Order, 1995. The “Raricap 40's Tablet” was originally manufactured by Ethnor Limited which was amalgamated with Johnson & Johnson Ltd. in the year 1994. The Government of India in exercise of its power under para 8 of DPCO, 1995 fixed the maximum retail selling price for “Raricap Tablet” at Rs. 16.24 for 40 tablets by order dated 7-8-1996. At the time when the order was made that drug was manufactured by Johnson & Johnson Ltd. The Johnson & Johnson Ltd. did not abide by the order and continued to sell the drugs at the rate of Rs. 24.57 for a packet of 40 tablets. It appears that Johnson & Johnson Ltd. stopped manufacturing the drug from 31-3-1997 and from 1-4-1997 N.R.J started manufacturing and selling that drug. It appears that Johnson & Johnson Ltd. had transferred the production rights and trade mark of “Raricap 40's” tablets to N.R Jet in July, 1996. It also appears that Johnson & Johnson Ltd. has filed a writ petition in Delhi High Court challenging the price fixation order and that petition is pending before the Delhi High Court. The order which is impugned in these petitions has been made pursuant to show cause notice dated 30-10-2002. The show cause notice dated 30-10-2002 was issued by the Director of respondent No. 1 to Johnson & Johnson Ltd. and N.R Jet, stating therein that “Raricap” tablets were being sold initially by Johnson & Johnson Ltd. until March, 1997 and subsequently by N.R Jet which is a unit of Johnson & Johnson Ltd., at a price higher than which is fixed by the order dated 7-8-1996. It was claimed that Johnson & Johnson Ltd. and N.R Jet in collusion have violated DPCO'95 by selling the drug at higher price. It was claimed that N.R Jet is nothing but an unit of Johnson & Johnson Ltd. The share holding pattern of N.R Jet was mentioned in detail in the notice and it was shown that N.R Jet is completely owned and controlled by Johnson & Johnson Ltd. Therefore, both the petitioners were asked to show cause why overcharged amount should not be recovered from them under the Essential Commodities Act and why amount of interest on that overcharged amount should not be recovered from them. Reply was submitted to the show cause notice. The reply submitted by Johnson & Johnson Ltd. was mainly that the order fixing maximum price of the drug is invalid and is not binding on it. The reply submitted by N.R Jet was basically that it is not an unit of Johnson & Johnson Ltd. and it is an independent entity and that the order fixing maximum price is not binding on it because the order has not been made against it but it has been made against Johnson & Johnson Ltd. only. N.R Jet and Johnson & Johnson both also denied their liability to pay interest on the overcharged amount. The respondent No. 1 made a detailed order dated 12-6-2003 holding that N.R Jet is nothing but the unit of Johnson & Johnson Ltd. and therefore, the order fixing maximum price made against Johnson & Johnson Ltd. was binding on N.R Jet and therefore, both Johnson & Johnson Ltd. and N.R Jet are liable to pay the overcharged amount. It was also held that they are also liable to pay interest on the overcharged amount.

3. The learned Counsel appearing for petitioners raised basically two submissions. Firstly, relying on the provisions of paragraph (8) of DPCO'95 it was submitted that in order that the order can bind an entity, a specific order fixing maximum price has to be made in relation to that entity. It was submitted that so far as the N.R Jet is concerned, admittedly, there is no such specific order made fixing maximum price and therefore, it cannot be said that N.R Jet had sold the drug at a price which is more than the maximum price fixed at DPCO'95. Insofar as Johnson & Johnson Ltd. is concerned, it was claimed that the order fixing maximum price is invalid. The validity of that order is challenged in Delhi High Court. It was also submitted that the respondent No. 1 was not justified in holding that N.R Jet is nothing but a unit of Johnson & Johnson Ltd. It is submitted that N.R Jet is an independent company incorporated under the Companies Act, and therefore, in order that the price control order made under paragraph (8) of DPCO'95 can bind N.R Jet, the order has to be made specifically against that Company. It was further submitted by referring to the provisions of section 7A of the Essential Commodities Act that for entitlement to charge interest over the amount arises only when default is made and the default must be by a person who is legally liable to make that payment. According to the petitioners, the liability to pay must be founded on a legally valid, justifiable and sustainable demand or claim. It was submitted that as the demand of excess amount itself is illegal and therefore, there is no liability to pay, consequently there is no question of any default. It was further submitted that under paragraph (13) of DPCO 1995 the Government can by notice require the manufacture, importer or distributor to deposit the amount accrued due to charging of prices higher than those fixed or notified by the Government. It is submitted that for an amount to have accrued, the liability must have been finally determined and only then it can be said that the liability has accrued and become due and payable. In the present case, the liability has been finally determined by the respondents by the impugned order dated 12-6-2003, and therefore, interest if at all can be charged only from that date and not from any date anterior to that. The principal submission on behalf of the respondents is that looking to the conduct of the petitioners this is not a fit case in which this Court should exercise its extraordinary jurisdiction under Article 226 of the Constitution of India in favour of the petitioners. It is submitted that when the order fixing maximum price was made, Johnson & Johnson Ltd. was manufacturing the drug; immediately after the order was made the trade mark and right to manufacture the drug were transferred by Johnson & Johnson Ltd. to N.R Jet which is a fully owned and controlled subsidiary of Johnson & Johnson. Even before the transfer was made to N.R Jet, Johnson & Johnson continued to sell the drug at higher price till 31-3-1997. It is submitted that though in the present proceedings Johnson & Johnson has been claiming that it is not liable to pay overcharged amount and that N.R Jet is not its subsidiary and unit, the overcharged amount of Rs. 22,35,72,889/- is paid by Johnson & Johnson itself. It is submitted that, therefore, there is no substance in the submission made on behalf of the petitioners that the price fixation is not binding on N.R Jet because it is not an unit of Johnson & Johnson. So far as the aspect of charging interest is concerned, it is submitted that as N.R Jet is nothing but an unit of Johnson & Johnson, the price fixation order was binding on it, and therefore, it will be liable to pay interest from the date on which it recovered the amount by overcharging. It was submitted that the dominant purpose of the provisions of Drugs Price Control Orders is to ensure availability of essential drugs to the consumers at a fair price and for that purpose the price control order fixing maximum price was made. Johnson & Johnson and N.R Jet in collusion with each other violated that order and defeated the scheme and therefore, according to the respondents, this Court should not interfere in favour of the petitioners.

4. Now firstly it was the case of the petitioners that the amount of Rs. 25,00,78,550/- has been wrongly calculated by the respondent No. 1 and therefore, according to the petitioners, they can be directed only to pay lesser amount. Now as a result of the written submissions filed in these petitions it is clear that the overcharged amount is not Rs. 25,00,78,550/- but it is actually Rs. 22,35,72,889/-, and therefore, the order impugned in the petition stands modified to that extent. However, so far as the amount of interest is concerned, no such grievance of the mistake in calculation has been made. Really speaking, so far as the overcharged amount is concerned, there is no dispute between the parties in these petitions because that amount admittedly has been deposited by Johnson & Johnson Ltd. and a statement was made before us that Johnson & Johnson does not intend to claim back that amount. Therefore, the only question to be considered in these petitions is whether the respondent No. 1 was justified in calculating the interest on the overcharged amount even from the date anterior to the date on which the order was made. For that purpose, it becomes necessary to decide whether the order fixing the price can be said to bind N.R Jet. Admittedly, the order fixing the price was made on 7-8-1996 at that time Johnson & Johnson Ltd. was manufacturing and selling the drug and therefore, the order was undoubtedly binding on Johnson & Johnson Ltd. Though the order was made on 7-8-1996, Johnson & Johnson Ltd. continued to sell the drug at a higher price than the maximum price fixed by the order dated 7-8-1996 till 31-3-1997 and after 1-4-1997 N.R Jet also continued to sell the drug at a price higher than the maximum price fixed by the order. The conclusion of the respondents that N.R Jet is nothing but a unit of Johnson & Johnson Ltd. is based on the admitted positions viz. (i) N.R Jet Enterprises has a paid up capital of Rs. 50,000/- divided in 5000 equity shares of Rs. 10/- each; (ii) these 5000 shares are equally held (i.e 1250 shares each) by four fully owned subsidiary companies of Johnson & Johnson Ltd., 30, Forjett Street, Bombay-36 namely (a) Loyalty Investments and Enterprises Ltd., (b) Suryalay Investment and Trading Co. Ltd., (c) Key to Riches Investments and Leasing Ltd., (d) Deshraj Investment and Leasing Company Ltd. The address of Johnson & Johnson Ltd. and the four companies who amongst themselves hold fully owned share capital of N.R Jet is same viz. 30, Forjett Street, Bombay-36. In the Director's report of these four companies, it is mentioned that none of these companies have any employees to conduct the day to day business activities. All the four companies are investment companies and they are fully owned and controlled by Johnson & Johnson Ltd. Thus, N.R Jet is fully owned and controlled by the four aforementioned companies who are fully owned and controlled by Johnson & Johnson. These facts are admitted and are not disputed by anybody. Despite raising a defence that N.R Jet is not an unit of Johnson & Johnson and that admittedly the drug was manufactured and sold by N.R Jet after 1-4-1997, the entire overcharged amount of Rs. 22,35,72,889/- has, admittedly, been paid by Johnson & Johnson Ltd. In our opinion, these facts leaves one in no doubt that N.R Jet is nothing but a outfit owned and controlled by Johnson & Johnson Ltd. What is further to be seen here is that the price control order was made against Johnson & Johnson Ltd. when it was manufacturing and selling the drug, obviously therefore, the order was binding on Johnson & Johnson Ltd. Johnson & Johnson transferred its trade mark of the drug and right to manufacture that drug to N.R Jet. Thus, N.R Jet is merely an assignee of Johnson & Johnson Ltd. If because of the order made fixing maximum price, the right of Johnson & Johnson Ltd. to manufacture and sell the drug was circumscribed by the requirement of selling the drug at the price fixed by the order then merely because right to manufacture and sell the drug is transferred by Johnson & Johnson Ltd. to N.R Jet will not take away the requirement of the assignee being bound by the said restriction. Being assigner Johnson & Johnson Ltd. could have transferred and N.R Jet could have received only those rights which Johnson & Johnson Ltd. had. All other things being the same, N.R Jet would be entitled to manufacture and sell the drug subject to same restrictions which were binding on Johnson & Johnson. It is thus, clear that the order fixing the maximum price was binding on Johnson & Johnson Ltd. as also on its unit viz. N.R Jet, therefore, both were under liability to sell the drugs only at the price fixed in the order. Admittedly, they have overcharged and therefore, they become liable to pay interest on overcharged amount from the date on which they have overcharged the amount. As we have found that N.R Jet is nothing but an unit of Johnson & Johnson and from day one it started selling the drug at a price higher than the one fixed in the order, and therefore, when it sold the drug at higher price and did not pay that amount to the Government on recovering higher amount, it becomes liable to pay interest on that amount. Thus, we do not find any reason to vary or set aside the order directing the petitioners to pay interest.

5. In our opinion, the respondents are also justified in saying that looking to the conduct of Johnson & Johnson Ltd. and N.R Jet this Court should decline to interfere in favour of Johnson & Johnson Ltd. and N.R Jet in exercise of its extraordinary jurisdiction under Article 226 of the Constitution of India. The whole scheme of transferring right to manufacture and trade mark to N.R Jet was created by Johnson & Johnson only to bypass the statutory order made by the authority fixing the maximum price at which the drug was to be sold. The purpose of the order fixing maximum price of the drug is to make the drug available to the consumer at a fair price. The order, therefore, obviously was in public interest. Therefore, the whole scheme was created by Johnson & Johnson Ltd. and N.R Jet in collusion with each other to defeat the order made in public interest and to defeat the public interest. In our opinion, therefore, their conduct dis-entitles them to any relief which is in the discretion of this Court. Technically speaking N.R Jet is a company incorporated under the Companies Act, and therefore, if manufacturing and selling of the drug was taken up by the N.R Jet independently, it would have been necessary for the authority under the drug price control order to make separate order fixing maximum price of the drug in relation to N.R Jet. But as we find that N.R Jet was merely a unit of Johnson & Johnson Ltd. and the whole scheme of manufacturing and selling of the drug by N.R Jet was a scheme employed by Johnson & Johnson Ltd. to defeat the provisions of drug price control order, in our opinion, no interference at the hands of this Court in its extraordinary jurisdiction is called for in favour of Johnson & Johnson Ltd. and N.R Jet. The Supreme Court in the judgment in the case Mohammad Swalleh v. IIIrd Addl. District Judge, Meerut, (1988) 1 SCC 40 : AIR 1988 SC 94 has held that High Court was justified in declining to exercise jurisdiction under Article 226 of the Constitution of India even after finding that the order that was challenged before the High Court in a petition filed under Article 226 of the Constitution of India was illegal. The Supreme Court has held that when the High Court finds that justice has been done by the order impugned before it in a petition filed under Article 226 of the Constitution of India, the High Court will be justified in declining to exercise its jurisdiction under Article 226 of the Constitution of India. Both the petitions, therefore, are disposed of. The order impugned in the petitions is not interfered with, save and except it is declared that instead of the amount Rs. 25,00,78,500/- the correct amount is Rs. 22,35,72,889/-. Rest of the order is confirmed. Rule is disposed of accordingly. No order as to costs.

xxx.